Extracellular matrix-derived scaffolds in constructing artificial ovaries for ovarian failure: a systematic methodological review.

IF 8.3 Q1 OBSTETRICS & GYNECOLOGY
Human reproduction open Pub Date : 2023-04-20 eCollection Date: 2023-01-01 DOI:10.1093/hropen/hoad014
Tong Wu, Ke-Cheng Huang, Jin-Feng Yan, Jin-Jin Zhang, Shi-Xuan Wang
{"title":"Extracellular matrix-derived scaffolds in constructing artificial ovaries for ovarian failure: a systematic methodological review.","authors":"Tong Wu, Ke-Cheng Huang, Jin-Feng Yan, Jin-Jin Zhang, Shi-Xuan Wang","doi":"10.1093/hropen/hoad014","DOIUrl":null,"url":null,"abstract":"<p><strong>Study question: </strong>What is the current state-of-the-art methodology assessing decellularized extracellular matrix (dECM)-based artificial ovaries for treating ovarian failure?</p><p><strong>Summary answer: </strong>Preclinical studies have demonstrated that decellularized scaffolds support the growth of ovarian somatic cells and follicles both <i>in vitro</i> and <i>in vivo</i>.</p><p><strong>What is known already: </strong>Artificial ovaries are a promising approach for rescuing ovarian function. Decellularization has been applied in bioengineering female reproductive tract tissues. However, decellularization targeting the ovary lacks a comprehensive and in-depth understanding.</p><p><strong>Study design size duration: </strong>PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from inception until 20 October 2022 to systematically review all studies in which artificial ovaries were constructed using decellularized extracellular matrix scaffolds. The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol.</p><p><strong>Participants/materials setting methods: </strong>Two authors selected studies independently based on the eligibility criteria. Studies were included if decellularized scaffolds, regardless of their species origin, were seeded with ovarian cells or follicles. Review articles and meeting papers were removed from the search results, as were articles without decellularized scaffolds or recellularization or decellularization protocols, or control groups or ovarian cells.</p><p><strong>Main results and the role of chance: </strong>The search returned a total of 754 publications, and 12 papers were eligible for final analysis. The papers were published between 2015 and 2022 and were most frequently reported as coming from Iran. Detailed information on the decellularization procedure, evaluation method, and preclinical study design was extracted. In particular, we concentrated on the type and duration of detergent reagent, DNA and extracellular matrix detection methods, and the main findings on ovarian function. Decellularized tissues derived from humans and experimental animals were reported. Scaffolds loaded with ovarian cells have produced estrogen and progesterone, though with high variability, and have supported the growth of various follicles. Serious complications have not been reported.</p><p><strong>Limitations reasons for caution: </strong>A meta-analysis could not be performed. Therefore, only data pooling was conducted. Additionally, the quality of some studies was limited mainly due to incomplete description of methods, which impeded specific data extraction and quality analysis. Several studies that used dECM scaffolds were performed or authored by the same research group with a few modifications, which might have biased our evaluation.</p><p><strong>Wider implications of the findings: </strong>Overall, the decellularization-based artificial ovary is a promising but experimental choice for substituting insufficient ovaries. A generic and comparable standard should be established for the decellularization protocols, quality implementation, and cytotoxicity controls. Currently, decellularized materials are far from being clinically applicable to artificial ovaries.</p><p><strong>Study funding/competing interests: </strong>This study was funded by the National Natural Science Foundation of China (Nos. 82001498 and 81701438). The authors have no conflicts of interest to declare.</p><p><strong>Trial registration number: </strong>This systematic review is registered with the International Prospective Register of Systematic Reviews (PROSPERO, ID CRD42022338449).</p>","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":null,"pages":null},"PeriodicalIF":8.3000,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174707/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human reproduction open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/hropen/hoad014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Study question: What is the current state-of-the-art methodology assessing decellularized extracellular matrix (dECM)-based artificial ovaries for treating ovarian failure?

Summary answer: Preclinical studies have demonstrated that decellularized scaffolds support the growth of ovarian somatic cells and follicles both in vitro and in vivo.

What is known already: Artificial ovaries are a promising approach for rescuing ovarian function. Decellularization has been applied in bioengineering female reproductive tract tissues. However, decellularization targeting the ovary lacks a comprehensive and in-depth understanding.

Study design size duration: PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from inception until 20 October 2022 to systematically review all studies in which artificial ovaries were constructed using decellularized extracellular matrix scaffolds. The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol.

Participants/materials setting methods: Two authors selected studies independently based on the eligibility criteria. Studies were included if decellularized scaffolds, regardless of their species origin, were seeded with ovarian cells or follicles. Review articles and meeting papers were removed from the search results, as were articles without decellularized scaffolds or recellularization or decellularization protocols, or control groups or ovarian cells.

Main results and the role of chance: The search returned a total of 754 publications, and 12 papers were eligible for final analysis. The papers were published between 2015 and 2022 and were most frequently reported as coming from Iran. Detailed information on the decellularization procedure, evaluation method, and preclinical study design was extracted. In particular, we concentrated on the type and duration of detergent reagent, DNA and extracellular matrix detection methods, and the main findings on ovarian function. Decellularized tissues derived from humans and experimental animals were reported. Scaffolds loaded with ovarian cells have produced estrogen and progesterone, though with high variability, and have supported the growth of various follicles. Serious complications have not been reported.

Limitations reasons for caution: A meta-analysis could not be performed. Therefore, only data pooling was conducted. Additionally, the quality of some studies was limited mainly due to incomplete description of methods, which impeded specific data extraction and quality analysis. Several studies that used dECM scaffolds were performed or authored by the same research group with a few modifications, which might have biased our evaluation.

Wider implications of the findings: Overall, the decellularization-based artificial ovary is a promising but experimental choice for substituting insufficient ovaries. A generic and comparable standard should be established for the decellularization protocols, quality implementation, and cytotoxicity controls. Currently, decellularized materials are far from being clinically applicable to artificial ovaries.

Study funding/competing interests: This study was funded by the National Natural Science Foundation of China (Nos. 82001498 and 81701438). The authors have no conflicts of interest to declare.

Trial registration number: This systematic review is registered with the International Prospective Register of Systematic Reviews (PROSPERO, ID CRD42022338449).

Abstract Image

Abstract Image

Abstract Image

细胞外基质衍生支架在构建人工卵巢治疗卵巢功能衰竭中的应用:系统方法学综述。
研究问题:目前评估基于脱细胞细胞外基质(dECM)的人工卵巢治疗卵巢功能衰竭的最先进方法是什么?临床前研究表明,脱细胞支架可在体外和体内支持卵巢体细胞和卵泡的生长:人工卵巢是拯救卵巢功能的一种有前途的方法。脱细胞技术已被应用于女性生殖道组织的生物工程。然而,针对卵巢的脱细胞技术还缺乏全面深入的了解:对PubMed、Embase、Web of Science和Cochrane Central Register of Controlled Trials进行了检索,系统回顾了从开始到2022年10月20日使用脱细胞细胞外基质支架构建人工卵巢的所有研究。综述按照系统综述和元分析首选报告项目(PRISMA)协议进行:两位作者根据资格标准独立选择研究。如果脱细胞支架(无论其物种来源)播种了卵巢细胞或卵泡,则纳入研究。检索结果中删除了综述文章和会议论文,也删除了没有脱细胞支架或再细胞化或脱细胞化方案、对照组或卵巢细胞的文章:搜索共检索到 754 篇论文,其中 12 篇符合最终分析条件。这些论文发表于 2015 年至 2022 年之间,其中来自伊朗的论文最多。我们提取了脱细胞程序、评估方法和临床前研究设计的详细信息。我们特别关注了去污试剂的类型和持续时间、DNA 和细胞外基质检测方法以及关于卵巢功能的主要发现。报告了来自人类和实验动物的脱细胞组织。装有卵巢细胞的支架可产生雌激素和孕激素,但差异很大,并支持各种卵泡的生长。尚未有关于严重并发症的报道:无法进行荟萃分析。谨慎原因:无法进行荟萃分析,因此只进行了数据汇总。此外,一些研究的质量有限,主要原因是方法描述不完整,妨碍了具体的数据提取和质量分析。有几项使用脱细胞模塑支架的研究是由同一个研究小组完成或撰写的,只做了一些修改,这可能会使我们的评估结果产生偏差:总的来说,基于脱细胞技术的人工卵巢是替代不足卵巢的一种很有前景的实验性选择。应为脱细胞方案、质量实施和细胞毒性控制制定通用的可比标准。目前,脱细胞材料还远未应用于人工卵巢的临床研究:本研究由国家自然科学基金资助(编号:82001498 和 81701438)。作者无利益冲突需要声明:本系统综述已在国际系统综述前瞻性注册中心(PROSPERO,ID CRD42022338449)注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.50
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信